R. Tanny Kang

About R. Tanny Kang

Tanny focuses his practice on advising global pharmaceutical companies, startup biotechs, and other technology companies on a variety of corporate, transactional, and commercial matters, including complex licensing and collaboration agreements, strategic alliances, operational agreements, mergers and acquisitions and divestment transactions.

During law school, Tanny served as a Senior Editor for the University of Pennsylvania Law Review and interned in the U.S. District Court for the District of Columbia in the chambers of the Honorable Rudolph Contreras.

Recent work

• Johnson & Johnson on its $13.1 billion pending acquisition of Shockwave Medical, Inc., a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified CAD and PAD.
• Merz Therapeutics on its $185 million pending acquisition of the assets of Acorda Therapeutics, Inc. through a court structured 363 sale process under the U.S. Bankruptcy Code, including rights to two commercially available medicines to treat phases of Parkinson's disease and gait disorders in multiple sclerosis.
• AstraZeneca on its $2.4 billion pending acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
• AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary Navacim^TM platform technology. 
• Novartis, as global transaction counsel, on the separation and spin-off of Sandoz, its generics and biosimilars division.
• SERB Pharmaceuticals on its license from SFJ Pharmaceuticals to obtain exclusive U.S. rights to bentracimab, a ticagrelor reversal agent.
• Innovation team of a leading healthcare provider on strategic technology and IP investments and transactions, including transactions involving novel SaMD, AI/ML and data analytic tools to improve healthcare delivery and outcomes.
• AbbVie on a strategic research collaboration and option to license HotSpot Therapeutics’ discovery-stage IRF5. small molecule allosteric therapy for the treatment of autoimmune diseases, including a $40 million upfront cash payment, an additional $295 million in option fees and R&D milestones, and the potential for commercial milestones and royalties.
• Sairopa on its collaboration, option and license agreement with Exelixis to produce novel oncology therapies
• Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc
• Moderna on its ten-year agreement with the State of Victoria to establish a state-of-the-art, domestic mRNA manufacturing facility at Monash University
• A prominent healthcare service provider on its long-term, strategic collaboration with a developer of patient care management software.